Scientific Advisory · Arlington, MA
Glastenbury
Scientific
Building tools. Building teams.
An independent scientific advisory firm at the intersection of platform biology, organizational design, and drug development strategy. Built on fifteen years of firsthand experience turning scientific vision into operational reality.
Designing and scaling the infrastructure that makes drug discovery work. Screening, NGS, automation, and delivery optimization, from early stage through IND readiness.
Building and structuring multidisciplinary discovery teams and operating models that accelerate scientific execution. Organizational design for companies moving fast and building for the long term.
Designing experiments, enforcing data standards, and building the referential frameworks that translate biological results into model-ready datasets. The interface between biology and computation, grounded in operational experience.
Expert platform assessment for VC and PE firms evaluating genome editing, RNA therapeutics, and delivery companies. Independent, specific, and grounded in firsthand experience.
Matt is a scientific builder with 15+ years developing the discovery platforms that enable genetic medicines to advance from hypothesis to clinic. Most recently Senior Director of Automated Screening, NGS, Protein Sciences and RNA Technologies at Prime Medicine, he built and scaled the infrastructure supporting 18+ therapeutic programs from target nomination to IND readiness.
Previously at Intellia Therapeutics, Matt supported NTLA-2001, the first-in-human in vivo CRISPR therapeutic for transthyretin amyloidosis, and contributed to NEJM-acknowledged programs in both CRISPR and prime editing. He trained as an immunologist at Harvard University.
Glastenbury Scientific is named for Glastenbury, Vermont, a 44-square-mile, nearly roadless wilderness township in the Green Mountains. Matt and his wife own an off-grid cabin on the Deerfield River, just east of the township line.
Advisory retainers, project-based consulting, fractional CSO/VP roles, SAB seats. If you are building in the high throughput genetic perturbation, genome editing, RNA therapeutics, or NGS space and need a scientific partner with deep firsthand platform experience, please reach out.